Cell of origin is not associated with outcomes of relapsed or refractory diffuse large B cell lymphoma

Sanjal H. Desai; Raphael Mwangi; Alexandra N. Smith; Matthew J. Maurer; Umar Farooq; Rebecca L. King; James R. Cerhan; Andrew L. Feldman; Thomas M. Habermann; Carrie A. Thompson; Yucai Wang; Stephen M. Ansell; Thomas E. Witzig; Grzegorz S. Nowakowski

doi:10.1002/hon.3098

Back

$Cell of origin is not associated with outcomes of relapsed or refractory diffuse large B cell lymphoma$

Journal article

Open access

Peer reviewed

Cell of origin is not associated with outcomes of relapsed or refractory diffuse large B cell lymphoma

Sanjal H. Desai, Raphael Mwangi, Alexandra N. Smith, Matthew J. Maurer, Umar Farooq, Rebecca L. King, James R. Cerhan, Andrew L. Feldman, Thomas M. Habermann, Carrie A. Thompson, …

Hematological oncology, Vol.41(1), pp.39-49

02/2023

DOI: 10.1002/hon.3098

PMCID: PMC10037910

PMID: 36305717

Files and links (1)

url

https://doi.org/10.1002/hon.3098View

Published (Version of record) Open Access

Abstract

Activated B cell (ABC) type diffuse large B cell lymphoma (DLBCL), double hit lymphoma (DHL) and double expressor lymphoma (DEL) have poor outcomes to frontline R-CHOP but impact of these molecular features on outcomes of relapsed/refractory (R/R) disease is not well-characterized. We evaluated the association of diagnostic cell of origin (COO), double hit and double expressor status with overall survival after first relapse in DLBCL patients who were enrolled into the Molecular Epidemiology Resource (MER) cohort. COO was available from immunohistochemistry (IHC) using Hans criteria or gene expression profiling (GEP) (Nanostring) on the diagnostic FFPE biopsy. Of 373 pts with R/R DLBCL, 278 had COO by IHC: 152 were GCB, 107 were non-GCB. One hundred and fourty had COO by GEP: 44 were ABC, 65 were GCB and 13 were unclassifiable. Nineteen out of 163 (12%) were DHL; 30 out of 135 (22%) had DEL. COO, either by IHC (2 years OS GCB: 45% [CI95: 38-54] vs. non-GCB: 44% [CI95:36-55], p > 0.05) or GEP (2 years OS ABC: 42% [CI95: 29-59] vs. GCB: 40% [CI95: 30-54], p > 0.05), was not associated with difference in OS. DHL (2 years OS 16 [CI95:6-45] vs. 45% [CI95: 34-59], p < 0.01) and DEL (2 years OS 33% [CI95: 20-56], vs. 50% [CI95: 41-60], p < 0.05) had lower OS than non-DHL and non-DEL/non-DHL counterparts, respectively. COO by IHC or GEP was not associated with OS in R/R DLBCL while DHL and DEL were adverse prognostic markers in DLBCL at first relapse.

Hematology

Oncology

Life Sciences & Biomedicine

Science & Technology

Details

Title: Subtitle: Cell of origin is not associated with outcomes of relapsed or refractory diffuse large B cell lymphoma
Creators: Sanjal H. Desai - University of Minnesota
Raphael Mwangi - Mayo Clinic
Alexandra N. Smith - Mayo Clinic
Matthew J. Maurer - Mayo Clinic
Umar Farooq - University of Iowa
Rebecca L. King - Mayo Clinic
James R. Cerhan - Mayo Clinic
Andrew L. Feldman - Mayo Clinic
Thomas M. Habermann - Mayo Clinic
Carrie A. Thompson - Mayo Clinic
Yucai Wang - Department of Hematology, Mayo Clinic, Rochester, MN, US.
Stephen M. Ansell - Mayo Clinic
Thomas E. Witzig - Department of Hematology, Mayo Clinic, Rochester, MN, US.
Grzegorz S. Nowakowski - Mayo Clinic
Resource Type: Journal article
Publication Details: Hematological oncology, Vol.41(1), pp.39-49
DOI: 10.1002/hon.3098
PMID: 36305717
PMCID: PMC10037910
NLM abbreviation: Hematol Oncol
ISSN: 0278-0232
eISSN: 1099-1069
Publisher: Wiley
Number of pages: 11
Grant note: P50 CA97274; U01 CA195568 / National Cancer Institute, National Institutes of Health; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)
Language: English
Electronic publication date: 11/07/2022
Date published: 02/2023
Academic Unit: Hematology, Oncology, and Blood & Marrow Transplantation; Epidemiology; Internal Medicine
Record Identifier: 9984359923302771

Metrics

22 Record Views

5 Times Cited - Web of Science

See more details